Astec Lifesciences Ltd (ASTEC) is currently trading at 568.10 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Astec LifeSciences is an integrated agrochemical and pharmaceutical intermediate manufacturer operating multiple facilities in Maharashtra, India, producing technical active ingredients, intermediates, bulk formulations and CDMO products, with exports to over 18 countries and a 67.03% holding by Godrej Agrovet Limited. Q4 FY26 revenue rose 34.0% year-on-year to ₹161.3 crore and FY26 consolidated total income increased 17.1% to ₹453.2 crore, reflecting stronger volumes across Enterprise and Contract Manufacturing segments and sequential improvement driven primarily by Enterprise volumes. Margins improved materially with consolidated EBITDA increasing to ₹11.8 crore in Q4FY26 from ₹6.3 crore in Q4FY25, while FY26 reported EBITDA reached breakeven at ₹0.5 crore versus a significant loss the prior year, signaling operational leverage from higher volumes and better product mix. Despite operating improvements, Astec LifeSciences reported a consolidated loss after exceptional items and tax of ₹80.9 crore in FY26, an improvement versus FY25 losses, with exceptional items related to revised labour code impacts identified and disclosed as regulatory-driven and non-recurring. Operational investments include commissioning a herbicide plant in FY25-26 and the April 2023 Adi Godrej Centre for Chemical Research and Development, positioning Astec LifeSciences to accelerate CDMO product commercialization and capture growing domestic and export demand.

Over the past 52 weeks, Astec Lifesciences Ltd has traded between a low of ₹512.35 and a high of ₹936.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Astec Lifesciences Ltd has a market capitalization of approximately 1,260.76. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Astec Lifesciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -15.85 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,260.76 Cr, Astec Lifesciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Astec Lifesciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Astec Lifesciences Ltd is -15.85. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The scheduled list includes Paytm parent One 97 Communications, REC, Tata Consumer Products, Mankind Pharma, Indian Overseas Bank, Bank of Maharashtra, ITC Hotels, Dalmia Bharat and APL Apollo Tubes, among others.

Astec LifeSciences reported a consolidated net loss of ₹18.78 crore for Q1 FY27 (quarter ended June 30, 2026).